News & Resources
Investors chronicle: 'Profit from artificial intelligence in neuroscience'
Published on investors chronicle: 22nd July, 2019 Author: Simon Thompson IXICO may be a small-cap London-based company well under the radar of investors, but it is highly regarded by pharmaceutical and biotechnology companies and huge corporations are increasingly awarding the company new contracts.
IXICO Webinar-Getting Neuroimaging Right — How to Succeed in Neurodegenerative Clinical Trials
An undisputed fact is that clinical trial delays are very costly. Any strategies that accelerate start-up are key to a study’s success in achieving timelines and expected budget. However, these drivers should not challenge the ultimate key objective of obtaining high-quality data without over-burdening the sites or the participants. In this webinar, the featured speakers will provide insights on how to address common challenges in neuroimaging studies.
What You Will Learn
- Attendees will be equipped with best practices for successful imaging, clinical study planning and management.
15th Clinical Trials on Alzheimer's Disease (CTAD)
The Clinical Trials on Alzheimer's Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease.
ECTRIMS 2022
Amsterdam, The Netherlands will play host to the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS 2022, on October 26–28.
View
MDS 2022 - International Congress of Parkinson’s Disease and Movement Disorders
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.
View
Current and Emerging Biomarkers to Advance Clinical Research in Parkinson’s Disease
Parkinson’s disease biomarker research continues to advance with the objectives of enabling earlier detection of neurodegeneration, elucidating disease mechanisms, identifying potential therapeutic targets as well as monitoring disease progression. While many promising biomarkers have been proposed, the ideal biomarker — with adequate sensitivity or specificity — remains elusive.
From α-synuclein to advanced magnetic resonance imaging (MRI) techniques, this webinar will cover both traditional Parkinson’s disease biomarkers and the potential utility of emerging biomarkers, such as microRNA (miRNA), microbiome and multimodal approaches.
Citing longitudinal research studies and recent clinical trials, the featured speakers will share the potential utility of fluid-based biomarkers and imaging biomarkers, discussing how each may help track drug efficacy and advance clinical trials.
Join this webinar to learn how fluid and imaging biomarkers can impact study design and patient selection in Parkinson’s disease clinical trials.
Presenters:
-Robert Martone, Associate Director, Labcorp Drug Development
-Hiba Kazmi, PhD, Biomarker Scientist, IXICO
-Antoniya Todorova, MD, PhD, Medical Director, Labcorp
AAIC 2022
Join us in San Diego and online for AAIC 2022, where the world’s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer’s disease.
View
AD/PD™ 2022
AD/PD™ 2022 brings a new look and a new chapter in the history of the AD/PD™ series of conferences. By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now transformed into an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
We are excited to provide improved opportunities for international medical and scientific professionals to come together and discuss the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
A central theme of the 2022 conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
97-104 of 155 results